Improving outcomes in the management of generalised Myasthenia Gravis (gMG)
.png){kind=spacer}
In this case-based module, we will review evidence-based therapeutic strategies tailored to managing highly active MG that remains refractory despite prior immunosuppressive therapies, emphasizing the importance of individualized, proactive treatment approaches.
All characters and events depicted in this patient case simulation are entirely fictitious. Any similarity to actual events or persons, living or dead, is purely coincidental. This activity is intended for a global audience of healthcare professionals.
This hypothetical case study is sponsored by Alexion, AstraZeneca Rare Disease. The content was developed with the assistance of Dr Renata Andrade, Unifesp Specialist in Neuromuscular Diseases at Unifesp RealNeuro, São Paulo, Brazil. This case study is promotional in nature and includes information on Alexion's products.
GL/ULT-g/0019 February 2025.
The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient.
For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Please note that products may have different product labeling according to geographical location. Within Europe, full prescribing information is available from the European Medicines Agency (https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf) and the Electronic Medicines Compendium. Prescribing information is also available from your local Alexion, AstraZeneca Rare Disease affiliate.